AnaptysBio Financial Statements (ANAB)
|
|
|
|
Report date
|
|
|
07.03.2022 |
01.03.2023 |
11.03.2024 |
27.02.2025 |
03.03.2026 |
|
12.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
63.2 |
10.3 |
17.2 |
91.3 |
234.6 |
|
232.4 |
|
Operating Income, bln rub |
|
|
-56.8 |
-115.2 |
-164.4 |
-114.9 |
47.9 |
|
40.8 |
|
EBITDA, bln rub |
? |
|
-55.7 |
-105.3 |
-156.4 |
-92.7 |
69.2 |
|
53.3 |
|
Net profit, bln rub |
? |
|
-57.8 |
-128.7 |
-163.6 |
-145.2 |
-13.2 |
|
-26.8 |
|
|
OCF, bln rub |
? |
|
-45.9 |
-73.6 |
-120.8 |
-135.3 |
19.7 |
|
4.48 |
|
CAPEX, bln rub |
? |
|
1.37 |
0.358 |
0.807 |
0.358 |
0.087 |
|
0.069 |
|
FCF, bln rub |
? |
|
-47.3 |
-74.0 |
-121.6 |
-135.7 |
19.6 |
|
4.41 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
21.5 |
36.6 |
49.3 |
42.4 |
184.3 |
|
229.7 |
|
Cost of production, bln rub |
|
|
98.5 |
88.8 |
132.3 |
163.8 |
2.42 |
|
177.8 |
|
R&D, bln rub |
|
|
98.5 |
88.8 |
139.6 |
163.8 |
136.0 |
|
128.7 |
|
Interest expenses, bln rub |
|
|
1.45 |
21.1 |
18.1 |
50.1 |
79.9 |
|
82.7 |
|
|
Assets, bln rub |
|
|
643.1 |
610.4 |
452.4 |
483.8 |
364.4 |
|
329.7 |
|
Net Assets, bln rub |
? |
|
356.4 |
262.1 |
88.1 |
70.9 |
37.2 |
|
12.7 |
|
Debt, bln rub |
|
|
21.0 |
19.5 |
17.8 |
369.5 |
14.1 |
|
277.4 |
|
Cash, bln rub |
|
|
548.1 |
441.2 |
390.9 |
385.4 |
311.6 |
|
286.5 |
|
Net debt, bln rub |
|
|
-527.1 |
-421.8 |
-373.1 |
-15.9 |
-297.5 |
|
-9.10 |
|
|
Ordinary share price, rub |
|
|
23.2 |
|
|
8.83 |
32.3 |
|
57.5 |
|
Number of ordinary shares, mln |
|
|
27.4 |
28.2 |
26.9 |
28.4 |
27.8 |
|
28.7 |
|
|
Market cap, bln rub |
|
|
636 |
0 |
0 |
251 |
898 |
|
1 650 |
|
EV, bln rub |
? |
|
108 |
-422 |
-373 |
235 |
601 |
|
1 641 |
|
Book value, bln rub |
|
|
356 |
262 |
88 |
71 |
37 |
|
13 |
|
|
EPS, rub |
? |
|
-2.11 |
-4.57 |
-6.08 |
-5.12 |
-0.48 |
|
-0.93 |
|
FCF/share, rub |
|
|
-1.72 |
-2.63 |
-4.52 |
-4.78 |
0.71 |
|
0.15 |
|
BV/share, rub |
|
|
13.0 |
9.31 |
3.27 |
2.50 |
1.34 |
|
0.44 |
|
|
EBITDA margin, % |
? |
|
-88.2% |
-1 023% |
-911.7% |
-101.6% |
29.5% |
|
23.0% |
|
Net margin, % |
? |
|
-91.5% |
-1 251% |
-953.7% |
-159.1% |
-5.64% |
|
-11.5% |
|
FCF yield, % |
? |
|
-7.44% |
|
|
-54.1% |
2.18% |
|
0.27% |
|
ROE, % |
? |
|
-16.2% |
-49.1% |
-185.7% |
-204.9% |
-35.6% |
|
-210.1% |
|
ROA, % |
? |
|
-8.99% |
-21.1% |
-36.2% |
-30.0% |
-3.63% |
|
-8.13% |
|
|
P/E |
? |
|
-11.0 |
0.00 |
0.00 |
-1.73 |
-67.9 |
|
-61.6 |
|
P/FCF |
|
|
-13.4 |
0.00 |
0.00 |
-1.85 |
45.8 |
|
374.2 |
|
P/S |
? |
|
10.1 |
0.00 |
0.00 |
2.75 |
3.83 |
|
7.10 |
|
P/BV |
? |
|
1.78 |
0.00 |
0.00 |
3.54 |
24.1 |
|
129.4 |
|
EV/EBITDA |
? |
|
-1.95 |
4.01 |
2.39 |
-2.53 |
8.67 |
|
30.8 |
|
Debt/EBITDA |
|
|
9.46 |
4.01 |
2.39 |
0.17 |
-4.30 |
|
-0.17 |
|
|
R&D/CAPEX, % |
|
|
7 211% |
24 804% |
17 301% |
45 765% |
156 287% |
|
186 451% |
|
|
CAPEX/Revenue, % |
|
|
2.16% |
3.48% |
4.70% |
0.39% |
0.04% |
|
0.03% |
|
| AnaptysBio shareholders |
